0001042187 false Q1 --12-31 0001042187 2023-01-01 2023-03-31 0001042187 2023-05-10 0001042187 2023-03-31 0001042187 2022-12-31 0001042187 us-gaap:RelatedPartyMember 2023-03-31 0001042187 us-gaap:RelatedPartyMember 2022-12-31 0001042187 2022-01-01 2022-03-31 0001042187 2021-12-31 0001042187 2022-03-31 0001042187 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001042187 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001042187 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001042187 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001042187 us-gaap:CommonStockMember 2021-12-31 0001042187 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001042187 us-gaap:RetainedEarningsMember 2021-12-31 0001042187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001042187 us-gaap:TreasuryStockCommonMember 2021-12-31 0001042187 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001042187 us-gaap:CommonStockMember 2022-12-31 0001042187 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001042187 us-gaap:RetainedEarningsMember 2022-12-31 0001042187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001042187 us-gaap:TreasuryStockCommonMember 2022-12-31 0001042187 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001042187 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001042187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001042187 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-03-31 0001042187 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001042187 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001042187 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001042187 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001042187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001042187 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001042187 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001042187 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001042187 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001042187 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0001042187 us-gaap:CommonStockMember 2022-03-31 0001042187 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001042187 us-gaap:RetainedEarningsMember 2022-03-31 0001042187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001042187 us-gaap:TreasuryStockCommonMember 2022-03-31 0001042187 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001042187 us-gaap:CommonStockMember 2023-03-31 0001042187 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001042187 us-gaap:RetainedEarningsMember 2023-03-31 0001042187 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001042187 us-gaap:TreasuryStockCommonMember 2023-03-31 0001042187 2023-03-30 2023-03-31 0001042187 CTIB:PNCAgreementsMember CTIB:PNCMember CTIB:TermLoanMember 2021-09-30 0001042187 CTIB:LineFinancialAgreementMember CTIB:LineFinancialMember CTIB:TermLoanMember 2021-09-30 0001042187 CTIB:LineFinancialAgreementMember us-gaap:PrimeRateMember 2023-03-31 0001042187 CTIB:LineFinancialAgreementMember us-gaap:PrimeRateMember 2023-03-30 2023-03-31 0001042187 CTIB:LineFinancialAgreementMember 2023-03-31 0001042187 CTIB:LineFinancialAgreementMember 2021-11-01 2021-11-01 0001042187 CTIB:LineFinancialAgreementMember 2021-09-01 2021-09-30 0001042187 CTIB:LineFinancialAgreementMember 2021-09-30 0001042187 CTIB:LineFinancialAgreementMember 2022-08-01 2022-08-31 0001042187 2021-12-30 2021-12-31 0001042187 srt:MaximumMember 2021-09-01 2021-09-30 0001042187 CTIB:TermLoanMember 2023-03-31 0001042187 CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2019-01-01 0001042187 CTIB:JohnHSchwanMember 2018-12-30 2019-01-01 0001042187 CTIB:JohnHSchwanMember us-gaap:CommonStockMember 2018-12-30 2019-01-01 0001042187 CTIB:JohnHSchwanMember us-gaap:CommonStockMember 2019-01-01 0001042187 CTIB:PromissoryNoteMember CTIB:JohnHSchwanMember 2023-03-31 0001042187 CTIB:PromissoryNoteMember CTIB:JohnHSchwanMember 2022-12-31 0001042187 CTIB:PromissoryNoteMember CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001042187 CTIB:PromissoryNoteMember CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2022-01-01 2022-03-31 0001042187 CTIB:AlexFengMember 2022-12-31 0001042187 CTIB:AlexFengMember 2022-01-01 2022-12-31 0001042187 CTIB:StockPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember 2020-01-02 2020-01-03 0001042187 CTIB:StockPurchaseAgreementMember us-gaap:SeriesAPreferredStockMember 2020-01-03 0001042187 us-gaap:SeriesAPreferredStockMember CTIB:AdditionalSharesOfferingMember 2020-01-02 2020-01-03 0001042187 us-gaap:SeriesAPreferredStockMember us-gaap:InvestorMember 2020-01-02 2020-01-03 0001042187 us-gaap:CommonStockMember CTIB:LFInternationalOfferingMember 2020-01-02 2020-01-03 0001042187 us-gaap:SeriesAPreferredStockMember 2020-01-02 2020-01-03 0001042187 us-gaap:SeriesAPreferredStockMember 2020-01-03 0001042187 us-gaap:SeriesAPreferredStockMember 2023-01-01 2023-03-31 0001042187 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:CommonStockMember CTIB:ConvertibleSeriesAPreferredStockMember 2022-09-01 0001042187 us-gaap:CommonStockMember CTIB:ConvertibleSeriesAPreferredStockMember 2022-09-01 2022-09-01 0001042187 us-gaap:SeriesBPreferredStockMember 2020-11-01 2020-11-30 0001042187 us-gaap:SeriesBPreferredStockMember 2020-11-30 0001042187 us-gaap:SeriesBPreferredStockMember 2023-03-31 0001042187 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001042187 us-gaap:CommonStockMember CTIB:ConvertibleSeriesCPreferredStockMember 2023-02-01 0001042187 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-01-31 0001042187 us-gaap:SeriesCPreferredStockMember 2021-01-31 0001042187 us-gaap:CommonStockMember CTIB:ConvertibleSeriesCPreferredStockMember 2022-09-01 0001042187 CTIB:UnrelatedThirdPartyMember us-gaap:SeriesDPreferredStockMember 2021-06-01 2021-06-30 0001042187 us-gaap:SeriesDPreferredStockMember 2021-09-29 2021-09-30 0001042187 us-gaap:SeriesDPreferredStockMember 2021-12-30 2021-12-31 0001042187 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001042187 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-12-31 0001042187 us-gaap:CommonStockMember CTIB:ConvertibleSeriesDPreferredStockMember 2022-09-01 0001042187 2022-12-31 2022-12-31 0001042187 2023-02-01 2023-02-01 0001042187 2020-12-31 0001042187 2020-01-01 2020-12-31 0001042187 2021-02-28 0001042187 2021-01-01 2021-02-28 0001042187 us-gaap:SeriesDPreferredStockMember 2021-02-28 0001042187 2021-01-01 2021-12-31 0001042187 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2022-01-01 2022-01-31 0001042187 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember 2022-01-31 0001042187 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember CTIB:TrailingTwelveMonthEBITDAEqualsOrExceedsOneMillionMember 2022-01-30 2022-01-30 0001042187 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember CTIB:CommonSharesTradeAtOrAbove5shareForTenOrMoreConsecutiveTradingDaysMember 2022-01-30 2022-01-30 0001042187 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember CTIB:OperatingCashFlowCalculatedCumulativelyFromTheDateOfEmploymentEqualsOrExceeds15MillionMember 2022-01-30 2022-01-30 0001042187 srt:ChiefExecutiveOfficerMember us-gaap:RestrictedStockMember CTIB:CompanyIsAbleToRefinanceItsCurrentLenderWithATraditionalLenderMember 2022-01-30 2022-01-30 0001042187 us-gaap:RestrictedStockMember srt:ChiefOperatingOfficerMember 2022-03-31 0001042187 us-gaap:RestrictedStockMember srt:ChiefOperatingOfficerMember 2022-01-01 2022-03-31 0001042187 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001042187 us-gaap:WarrantMember 2022-12-31 0001042187 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001042187 us-gaap:WarrantMember 2023-03-31 0001042187 CTIB:TwoThousandAndTwentyOneWarrantsMember 2023-03-31 0001042187 CTIB:CustomersAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-03-31 0001042187 CTIB:CustomersBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-03-31 0001042187 CTIB:CustomersAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001042187 CTIB:CustomersBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001042187 CTIB:CustomersAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-03-31 0001042187 CTIB:CustomersBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-03-31 0001042187 CTIB:CustomersAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001042187 CTIB:CustomersBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001042187 CTIB:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001042187 CTIB:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001042187 CTIB:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0001042187 CTIB:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001042187 CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2023-03-31 0001042187 CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2022-12-31 0001042187 CTIB:JohnHSchwanMember 2023-01-01 2023-03-31 0001042187 CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001042187 CTIB:JohnHSchwanMember us-gaap:RelatedPartyMember 2022-01-01 2022-03-31 0001042187 CTIB:LeaseAgreementMember 2020-07-01 2020-07-31 0001042187 CTIB:LeaseAgreementMember 2023-01-01 2023-03-31 0001042187 CTIB:LeaseAgreementMember 2021-03-01 2021-03-31 0001042187 CTIB:LeaseAgreementMember 2021-03-31 0001042187 CTIB:LeaseAgreementMember 2022-03-31 0001042187 CTIB:LeaseAgreementMember 2021-12-31 0001042187 us-gaap:SubsequentEventMember 2023-04-01 2023-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CTIB:Integer CTIB:Customers

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2023

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________to__________

 

Commission File Number

000-23115

 

YUNHONG CTI LTD.

(Exact name of registrant as specified in its charter)

 

Illinois   36-2848943
(State or other jurisdiction of  

(I.R.S. Employer

incorporation or organization)   Identification No.)

 

22160 N. Pepper Road    
Barrington, Illinois   60010
(Address of principal executive offices)   (Zip Code)

 

(847)382-1000

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

Common Stock, no par value per share   CTIB  

The Nasdaq Stock Market LLC

        (The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares outstanding of the registrant’s common stock, no par value per share, as of May 10, 2023 was 19,971,755 (excluding treasury shares).

 

 

 

 

 

 

INDEX

 

PART I – FINANCIAL INFORMATION  
     
Item No. 1. Financial Statements  
  Condensed Consolidated Balance Sheets at March 31, 2023 (unaudited) and December 31, 2022 (audited) 1
  Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three months ended March 31, 2023 and March 31, 2022 2
  Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2023 and March 31, 2022 3
  Condensed Consolidated Statements of Shareholders’ Equity (unaudited) for the three months ended March 31, 2023 and March 31, 2022 4
  Notes to Condensed Consolidated Financial Statements (unaudited) 5
Item No. 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
Item No. 3 Quantitative and Qualitative Disclosures Regarding Market Risk 18
Item No. 4 Controls and Procedures 18
     
PART II – OTHER INFORMATION
     
Item No. 1 Legal Proceedings 19
Item No. 1A Risk Factors 19
Item No. 2 Unregistered Sales of Equity Securities and Use of Proceeds 19
Item No. 3 Defaults Upon Senior Securities 19
Item No. 4 Mine Safety Disclosures 19
Item No. 5 Other Information 19
Item No. 6 Exhibits 20
  Signatures 21
  Exhibit 31.1  
  Exhibit 31.2  
  Exhibit 32  

 

 

 

Yunhong CTI, LTD

Condensed Consolidated Balance Sheets

 

   March 31, 2023   December 31, 2022 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $130,000   $146,000 
Accounts receivable, net   3,344,000    1,618,000 
Inventories   7,944,000    8,325,000 
Prepaid expenses   489,000    389,000 
           
Total current assets   11,907,000    10,478,000 
           
Property, plant and equipment:          
Machinery and equipment   17,723,000    17,723,000 
Office furniture and equipment   2,084,000    2,084,000 
Intellectual property   783,000    783,000 
Leasehold improvements   39,000    39,000 
Fixtures and equipment at customer locations   519,000    519,000 
Projects under construction   164,000    108,000 
Property, plant and equipment, gross   21,312,000    21,256,000 
Less : accumulated depreciation and amortization   (20,414,000)   (20,334,000)
           
Total property, plant and equipment, net   898,000    922,000 
           
Other assets:          
Operating lease right-of-use   3,757,000    3,882,000 
           
Total other assets   3,757,000    3,882,000 
           
TOTAL ASSETS  $16,562,000   $15,282,000 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Trade payables  $1,278,000   $1,313,000 
Line of credit   4,284,000    2,878,000 
Notes payable - current portion   540,000    289,000 
Notes payable - officers, subordinated   1,286,000    - 
Operating Lease Liabilities   518,000    518,000 
Accrued liabilities   1,382,000    2,480,000 
           
Total current liabilities   9,288,000    7,478,000 
           
Long-term liabilities:          
Notes payable - noncurrent   -    427,000 
Notes payable - officers, subordinated   -    1,267,000 
Operating Lease Liabilities   3,239,000    3,364,000 
           
Total long-term liabilities   3,239,000    5,058,000 
           
TOTAL LIABILITIES   12,527,000    12,536,000 
           
Shareholders’ Equity:          
Yunhong CTI, Ltd shareholders’ equity:          
Series B Preferred Stock — no par value, 170,000 shares authorized, none and 170,000 issued and outstanding at March 31, 2023 and December 31, 2022, respectively   -    1,851,000 
Common Stock – no par value, 50,000,000 shares authorized, 20,015,413 and 16,102,749 shares issued and 19,971,755 and 16,059,991 shares outstanding at March 31, 2023 and December 31, 2022, respectively   21,283,000    21,283,000 
Paid-in-capital   6,637,000    3,895,000 
Accumulated deficit   (23,724,000)   (24,122,000)
Less: Treasury stock, 43,658 shares   (161,000)   (161,000)
           
Total Shareholders’ Equity   4,035,000    2,746,000 
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $16,562,000   $15,282,000 

 

See accompanying notes to condensed consolidated unaudited financial statements.

 

1

 

Yunhong CTI, LTD

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

 

   2023   2022 
  

For the Three Months Ended

March 31,

 
   2023   2022 
         
Net Sales  $5,051,000   $5,797,000 
           
Cost of Sales   3,924,000    4,758,000 
           
Gross profit   1,127,000    1,039,000 
           
Operating expenses:          
General and administrative   961,000    837,000 
Selling   32,000    38,000 
Advertising and marketing   122,000    183,000 
           
Total operating expenses   1,115,000    1,058,000 
           
Income / (Loss) from operations   12,000    (19,000)
           
Other (expense) / income:          
Interest expense   (142,000)   (96,000)
Other (expense) / income   526,000    94,000 
           
Total other (expense) / income, net   384,000    (2,000)
           
Income / (Loss) from continuing operations before taxes   396,000    (21,000)
           
Income tax expense   -    - 
           
Net Income / (Loss)  $396,000   $(21,000)
           
Net Loss attributable to noncontrolling interest   -    - 
           
Net Loss attributable to Yunhong CTI Ltd.   396,000    (21,000)
           
Other Comprehensive Income (Loss)          
Foreign Currency adjustment   -      
Comprehensive Loss   396,000    (21,000)
           
Deemed Dividends on preferred stock and amortization of beneficial conversion feature  $(11,000)  $(202,000)
           
Net Loss attributable to Yunhong CTI Ltd Common Shareholders  $385,000   $(223,000)
           
Basic income (loss) per common share  $0.02   $(0.04)
           
Diluted income (loss) per common share  $0.02   $(0.04)
           
Weighted average number of shares and equivalent shares of common stock outstanding:          
Basic   17,689,552    5,900,639 
           
Diluted   17,689,552    5,900,639 

 

See accompanying notes to condensed consolidated unaudited financial statements.

 

2

 

Yunhong CTI, LTD

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

   2023   2022 
   For the Three Months Ended March 31, 
   2023   2022 
         
Cash flows from operating activities:          
Net income/loss from continuing operations  $396,000   $(21,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities          
Depreciation and amortization   80,000    98,000 
Equity compensation expense   7,000    31,000 
Provision for losses on accounts receivable   -    - 
Change in assets and liabilities:          
Accounts receivable   (1,726,000)   125,000 
Inventories   381,000    (620,000)
Prepaid expenses and other assets   (100,000)   339,000 
Trade payables   (35,000)   215,000 
Accrued liabilities   (372,000)   (167,000)
           
Net cash (used in) provided by operating activities   (1,369,000)   2,000 
           
Cash flows from investing activities:          
Purchases of property, plant and equipment   (56,000)   (15,000)
           
Net cash used in investing activities   (56,000)   (15,000)
           
Cash flows from financing activities:          
Proceeds from issuance of long-term debt and revolving line of credit   1,409,000    155,000 
           
Net cash provided by financing activities   1,409,000    155,000 
           
Net (decrease) / increase in cash and cash equivalents   (16,000)   142,000 
           
Cash and cash equivalents at beginning of period   146,000    66,000 
           
Cash and cash equivalents at end of period  $130,000   $208,000 
           
Supplemental disclosure of cash flow information and noncash investing and financing activities:          
Cash payments for interest  $118,000   $78,000 
Accrued Divided and Accretion on preferred stock  $11,000   $202,000 
Lease right-of-use assets and lease liability  $-   $747,000 
Conversion of notes and deposits into common stock  $885,000   $- 

 

See accompanying notes to condensed consolidated unaudited financial statements.

 

3

 

Yunhong CTI, Ltd

Consolidated Statements of Stockholders’ Equity

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Earnings    Shares   Amount   TOTAL 
   Yunhong CTI, Ltd     
   Series A Preferred Stock   Series B Preferred Stock   Series C Preferred Stock   Series D Preferred Stock   Common Stock   Paid-in  

Accumulated

(Deficit)

  

Less

Treasury Stock

     
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Earnings   Shares   Amount   TOTAL 
                                                             
Balance December 31, 2021   500,000   $3,155,000    170,000   $1,715,000    170,000   $1,630,000    170,000   $1,512,000    5,930,408   $14,538,000   $4,317,000   $(22,655,000) -  (44,000)  $(161,000)   4,051,000 
Accrued Deemed Dividend - Series A Preferred Stock        100,000                                            (100,000)                  - 
Accrued Deemed Dividend - Series B Preferred Stock                  34,000                                  (34,000)                  - 
Accrued Deemed Dividend - Series C Preferred Stock                            34,000                        (34,000)                  - 
Accrued Deemed Dividend - Series D Preferred Stock                                      34,000              (34,000)                  - 
Stock Issuance                                           25,000                             - 
Equity Compensation Charge                                                     31,000                   31,000 
Net Income (Loss)   -                                                       (21,000) -  -     -     (21,000)
Balance March 31, 2022   500,000   $3,255,000    170,000   $1,749,000    170,000   $1,664,000    170,000   $1,546,000    5,955,408   $14,538,000   $4,146,000   $(22,676,000) -  (44,000)  $(161,000)   4,061,000 

 

Yunhong CTI, Ltd

Consolidated Statements of Stockholders’ Equity

 

   Shares   Amount   Shares   Amount   Capital   Earnings   Loss   Shares   Amount   TOTAL 
   Yunhong CTI, Ltd     
                           Accumulated        
   Series B Preferred Stock   Common Stock   Paid-in   Accumulated (Deficit)  

Other

Comprehensive

  

Less

Treasury Stock

     
   Shares   Amount   Shares   Amount   Capital   Earnings   Loss   Shares   Amount   TOTAL 
                                         
Balance December 31, 2022   170,000   $1,851,000    16,102,749   $21,283,000   $3,895,000   $(24,122,000)  $-    (44,000)  $(161,000)   2,746,000 
                                                   
Series B Convertible Preferred Stock Issuance   (170,000)   (1,862,000)   1,888,078         1,862,000                        - 
Common stock issued for notes payable and investor deposit             1,908,336         884,000                        884,000 
Accrued Deemed Dividend - Series B Preferred Stock        11,000              (11,000)                       - 
Equity compensation             116,250         7,000                       9,000 
Net Income (Loss)                            396,000                   396,000 
Foreign Currency Translation                            -     -         -     - 
Balance March 31, 2023   -   $-    20,015,413   $21,283,000   $6,637,000   $(23,724,000)  $           -    (44,000)  $(161,000)   4,035,000 

 

See accompanying notes to unaudited condensed consolidated financial statements

 

4

 

Yunhong CTI Ltd. and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

 

Note 1 - Basis of Presentation

 

The accompanying condensed (a) consolidated balance sheet as of March 31, 2023 and (b) the unaudited interim condensed consolidated financial statements have been prepared and, in the opinion of management, contain all the adjustments (consisting of those of a normal recurring nature) considered necessary to present fairly the consolidated financial position and the consolidated statements of comprehensive income and consolidated cash flows for the periods presented in conformity with generally accepted accounting principles for interim consolidated financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2022, filed on April 12, 2023, which can be found on the Company’s website (www.ctiindustries.com) or www.sec.gov.

 

Principles of consolidation and nature of operations:

 

Yunhong CTI Ltd and its inactive subsidiary CTI Supply, Inc. (collectively, the “Company”) (i) design, manufacture and distribute metalized balloon products throughout the world, (ii) distribute purchased latex balloons products, and (iii) operate systems for the production, lamination, coating and printing of films used for food packaging and other commercial uses and for conversion of films to flexible packaging containers and other products. As discussed in Note 2 Discontinued Operations, effective in the third quarter of 2019, the Company determined that it was exiting the business formerly conducted by CTI Europe GmbH (“CTI Europe”). In addition, during October 2021, the Company sold its Mexican subsidiary (Flexo Universal, S. de R.L. de C.V.), a manufacturer of latex balloons. Accordingly, the operations of these entities are classified as discontinued operations in these financial statements.

 

The condensed consolidated financial statements include the accounts of Yunhong CTI Ltd., and CTI Supply, Inc. See Note 2.

 

The determination of whether or not to consolidate a variable interest entity under U.S. GAAP requires a significant amount of judgment concerning the degree of control over an entity by its holders of variable interest. To make these judgments, management has conducted an analysis of the relationship of the holders of variable interest to each other, the design of the entity, the expected operations of the entity, which holder of variable interests is most “closely associated” to the entity and which holder of variable interests is the primary beneficiary required to consolidate the entity. Upon the occurrence of certain events, management reviews and reconsiders its previous conclusion regarding the status of an entity as a variable interest entity.

 

Reclassification:

 

Certain amounts in the Company’s condensed consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods.

 

Use of estimates:

 

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the amounts reported of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period in the financial statements and accompanying notes. Actual results may differ from those estimates. The Company’s significant estimates include valuation allowances for doubtful accounts and inventory valuation, preferred stock dividends and beneficial conversion features, and assumptions used as inputs in the Black-Scholes option-pricing model.

 

Segments:

 

The Company operates as a single segment, both in terms of geography and operations, particularly in light of the October 2021 sale of its Flexo Universal subsidiary. After that date, all manufacturing occurs in the United States.

 

5

 

Earnings per share:

 

Basic (loss) per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period.

 

Diluted (loss) per share is computed by dividing the net loss by the weighted average number of shares of common stock and equivalents (stock options and warrants), unless anti-dilutive, during each period.

 

As of March 31, 2023 and 2022, shares to be issued upon the exercise of options and warrants aggregated 128,000 and 128,000, respectively. The number of shares included in the determination of earnings on a diluted basis for the three months ended March 31, 2023 and 2022 were none, as doing so would have been anti-dilutive.

 

Significant Accounting Policies:

 

The Company’s significant accounting policies are summarized in Note 2 of the Company’s consolidated financial statements for the year ended December 31, 2022. There were no significant changes to these accounting policies during the three months ended March 31, 2023.

 

Net sales include revenues from sales of products and shipping and handling charges, net of estimates for product returns. Revenue is measured at the amount of consideration the Company expects to receive in exchange for the transferred products. Revenue is recognized at the point in time when we transfer the promised products to the customer and the customer obtains control over the products. The Company recognizes revenue for shipping and handling charges at the time the goods are shipped to the customer, and the costs of outbound freight are included in cost of sales, as we have elected the practical expedient included in ASC 606.

 

The Company provides for product returns based on historical return rates. While we incur costs for sales commissions to our sales employees and outside agents, we recognize commission costs concurrent with the related revenue, as the amortization period is less than one year and we have elected the practical expedient included in ASC 606. We do not incur incremental costs to obtain contracts with our customers. Our product warranties are assurance-type warranties, which promise the customer that the products are as specified in the contract. Therefore, the product warranties are not a separate performance obligation and are accounted for 3s described herein. Sales taxes assessed by governmental authorities are accounted for on a net basis and are excluded from net sales.

 

6

 

Note 2 – Liquidity and Going Concern

 

The Company’s financial statements are prepared using accounting principles generally accepted in the United States (“U.S. GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a cumulative net loss from inception to March 31, 2023 of approximately $23 million. The accompanying financial statements for the three months ended March 31, 2023 have been prepared assuming the Company will continue as a going concern. The Company’s cash resources from operations may be insufficient to meet its anticipated needs during the next twelve months. If the Company does not execute its plan, it may require additional financing to fund its future planned operations.

 

The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses. Management’s plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing, continuing to focus our Company on the most profitable elements, and exploring alternative funding sources on an as needed basis. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The COVID-19 pandemic, supply chain challenges, and inflationary pressures have impacted the Company’s business operations to some extent and is expected to continue to do so and, these impacts may include reduced access to capital. The ability of the Company to continue as a going concern may be dependent upon its ability to successfully secure other sources of financing and attain profitable operations. There is substantial doubt about the ability of the Company to continue as a going concern for one year from the issuance of the accompanying consolidated financial statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The Company’s primary sources of liquidity have traditionally been comprised of cash and cash equivalents as well as availability under the Credit Agreement in place at the time (see Note 4). We endured compliance failures with covenants until September 2021 when we refinanced our credit facility. We believe we have been in compliance with our new credit facility since that time. This credit facility concludes on September 30, 2023. While we expect to obtain a new facility on acceptable terms, there can be no assurance this will occur, particularly in light of increasingly conservative financial markets.

 

7

 

Note 3 - Debt

 

On September 30, 2021 (the “Closing Date”), the Company entered into a loan and security agreement (the “Agreement”) with Line Financial (the “Lender”), which provides for a senior secured financing consisting of a revolving credit facility (the “Revolving Credit Facility) in an aggregate principal amount of up to $6 million (the “Maximum Revolver Amount”) and term loan facility (the “Term Loan Facility”) in an aggregate principal amount of $0.7 million (“Term Loan Amount” and, together with the Revolving Credit Facility, the “Senior Facilities”). Proceeds of loans borrowed under the Senior Facilities were used to repay all amounts outstanding under the Company’s previous lending agreements and for the Company’s working capital. The Senior Facilities are secured by substantially all assets of the Company.

 

Interest on the Senior Facilities shall be the prime rate published from time to time published in the Wall Street Journal (8% as of March 31, 2023), plus 1.95% per annum, accruing daily and payable monthly. Interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. The Term Loan Facility shall be repaid by the Company to Lender in 48 equal monthly installments of principal and interest, each in the amount of $15,000, commencing on November 1, 2021, and continuing on the first day of each month thereafter until the Term Loan Maturity Date (as defined in the Agreement). Also, the Company paid the Lender collateral monitoring fees of 4.62% of the eligible accounts receivable, inventory, and equipment supporting the Revolving Credit Facility and the Term Loan. In addition, the Company paid the Lender a loan fee of 1.25% of the Maximum Revolver Amount and the Term Loan Amount upon the execution of the Agreement. During August 2022 the terms were modified to reduce the collateral monitoring fee to 2.77% and added a provision that barred the Company from repaying the facility prior to September 2023.

 

The Senior Facilities mature on September 30, 2023 and shall automatically be extended for successive periods of one year each, unless the Company or the Lender gives the other party written notice of termination not less than 90 days prior to the end of such term or renewal term, as applicable. If the Senior Facilities are renewed, the Company shall pay the Lender a renewal fee of 1.25% of the Maximum Revolver Amount and the Term Loan Amount upon each renewal on the anniversary of the Closing Date. The Company has the option to prepay the Term Loan Facility (together with all accrued but unpaid interest and a Term Loan Prepayment Fee (as defined the Agreement) in whole, but not in part, upon not less than 60 days prior written notice to the Lender.

 

The Senior Facilities require that the Company shall, commencing December 31, 2021, maintain Tangible Net Worth of at least $4,000,000 or greater (“Minimum Tangible Net Worth”). Minimum Tangible Net Worth may be adjusted downward by the Lender, from time to time, in its sole and absolute discretion, based on the effect of non-cash charges and other factors on the calculation of Tangible Net Worth. Other debt subordinated to Lender is not considered as a reduction of this calculation. The Company believes it was in compliance with this covenant as of March 31, 2023 and December 31, 2022, respectively.

 

The Senior Facilities contain certain affirmative and negative covenants that limit the ability of the Company, among other things and subject to certain significant exceptions, to incur debt or liens, make investments, enter into certain mergers, consolidations, and acquisitions, pay dividends and make other restricted payments, or make capital expenditures exceeding $1,000,000 in the aggregate in any fiscal year.

 

As of March 31, 2023, the term loan balance amounted to $0.5 million, which consisted of the principal and interest payable balance of $0.6 million and deferred financing costs of $0.1 million. The balance of the Revolving Line of Credit as of March 31, 2023 and December 31, 2022 amounted to $4,284,000 and $2,878,000, respectively.

 

As of January 1, 2019, the Company had a note payable to John H. Schwan, Director and former Chairman of the Board, for $1.6 million, including accrued interest. This loan accrues interest, is due December 31, 2023, and is subordinate to the Senior Facilities. During January 2019, Mr. Schwan converted $600,000 of the note into approximately 181,000 shares of our common stock at the then market rate of $3.32 per share. As a result of the conversion, the loan balance decreased to $1 million. The loan and interest payable to Mr. Schwan amounted to $1.3 million as of March 31, 2023 and December 31, 2022, respectively. No payments were made to Mr. Schwan during 2023 or 2022. Interest expense related to this loan amounted to $18,000 and $17,000 for the three months ended March 31, 2023 and 2022, respectively.

 

As of December 31, 2022, the Company had a note payable to Alex Feng for $0.2 million. This loan accrued interest at a rate of 3% and is subordinated to the Senior Facilities. In accordance with the subordination agreement, payments may be made beginning April 2022 subject to availability under the revolving line of credit, and the maturity date for this loan is March 2024. Along with certain deposits received during 2022, this note was converted into common stock during February 2023.

 

8

 

Note 4 - Shareholders’ Equity

 

Series A Convertible Preferred Stock

 

On January 3, 2020, the Company entered into a stock purchase agreement (as amended on February 24, 2020 and April 13, 2020 (the “LF Purchase Agreement”)), pursuant to which the Company agreed to issue and sell, and LF International Pte. Ltd., a Singapore private limited company (“LF International”), which is controlled by Company director, Chairman, President and Chief Executive Officer, Mr. Yubao Li, agreed to purchase, up to 500,000 shares of the Company’s newly created shares of Series A Preferred Stock (“Series A Preferred”), with each share of Series A Preferred initially convertible into ten shares of the Company’s common stock, at a purchase price of $10.00 per share, for aggregate gross proceeds of $5,000,000 (the “LF International Offering”). As permitted by the Purchase Agreement, the Company may, in its discretion issue up to an additional 200,000 shares of Series A Preferred for a purchase price of $10.00 per share (the “Additional Shares Offering,” and collectively with the LF International Offering, the “Offering”). Approximately $1 million of Series A Preferred has been sold, including to an investor which converted an account receivable of $478,000 owed to the investor by the Company in exchange for 48,200 shares of Series A Preferred. The Company completed several closings with LF International from January 2020 through June 2020. The majority of the funds received reduced our bank debt. We issued a total of 400,000 shares of common stock to LF International and, pursuant to the LF Purchase Agreement, changed our name from CTI Industries Corporation to Yunhong CTI Ltd. LF International has the right to name three directors to serve on our Board. They were Mr. Yubao Li, Ms. Wan Zhang and Ms. Yaping Zhang. Ms. Wan Zhang and Ms. Yaping Zhang retired from the Board in January 2022.

 

The issuance of the Series A Preferred generated a beneficial conversion feature (BCF), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective strike price that is less than the market price of the underlying stock at the commitment date. The fair value of the common stock into which the Series A Preferred was convertible exceeded the allocated purchase price fair value of the Series A Preferred Stock at the closing dates by approximately $2.5 million as of the closing dates. We recognized this BCF by allocating the intrinsic value of the conversion option, to additional paid-in capital, resulting in a discount on the Series A Preferred. As the Series A Preferred is immediately convertible, the Company accreted the discount on the date of issuance. The accretion was recognized as dividend equivalents. Holders of the Series A Preferred were entitled to receive quarterly dividends at the annual rate of 8% of the stated value ($10 per share). Such dividends may be paid in cash or in shares of common stock at the Company’s discretion. In the three months ended March 31, 2023 and 2022 the Company accrued none and $100,000 of these dividends in each period, respectively, as the investor converted Series A Convertible Preferred Stock into common stock on September 1, 2022. This conversation resulted in the issuance of 5 million shares of common stock plus an additional approximately 1.3 million shares of common stock representing the accrued dividends.

 

Series B Convertible Preferred Stock

 

In November 2020, we issued 170,000 shares of Series B Preferred for an aggregate purchase price of $1,500,000. The Series B Preferred have an initial stated value of $10.00 per share and liquidation preference over common stock. The Series B Preferred is convertible into shares of our common stock equal to the number of shares determined by dividing the sum of the stated value and any accrued and unpaid dividends by the conversion price of $1.00. The Series B Preferred accrues dividends at a rate of 8 percent per annum, payable at our election either in cash or shares of the Company’s common stock. Initially, the Series B Preferred, in whole or part, was redeemable at the option of the holder (but not mandatorily redeemable) at any time on or after November 30, 2021 for the stated value, plus any accrued and unpaid dividends and thus was classified as mezzanine equity and initially recognized at fair value of $1.5 million (the proceeds on the date of issuance). The carrying value as of March 31, 2023 and December 31, 2022 amounted to none and $1,851,000, respectively. On February 1, 2023, the investor converted Series B Preferred into approximately 1.9 million shares of common stock, including accrued dividends.

 

Series C Convertible Preferred Stock

 

In January 2021 we entered into an agreement with a related party, LF International Pte. Ltd. which is controlled by Company director and Chairman, Mr. Yubao Li, to purchase shares of Series C Preferred stock. We issued 170,000 shares of Series C Preferred for an aggregate purchase price of $1,500,000. The Series C Preferred have an initial stated value of $10.00 per share and liquidation preference over common stock. The Series C Preferred is convertible into shares of our common stock equal to the number of shares determined by dividing the sum of the stated value and any accrued and unpaid dividends by the conversion price of $1.00. The Series C Preferred accrues dividends at a rate of 8 percent per annum, payable at our election either in cash or shares of the Company’s common stock. The issuance of the Series C Preferred generated a beneficial conversion feature (BCF), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective strike price that is less than the market price of the underlying stock at the commitment date. The fair value of the common stock into which the Series C Preferred was convertible exceeded the allocated purchase price of the Series C Preferred at the closing dates by greater than the allocated purchase price. Therefore, the BCF was the purchase price of the Series C Preferred ($1.5 million) and was allocated to Additional Paid-in Capital, resulting in a discount on the Series C Preferred Stock. As the Series C Preferred Stock is immediately convertible, the Company accreted the discount on the date of issuance. The accretion to the carrying value of the Series C Preferred is treated as a deemed dividend, recorded as a charge to Additional Paid in Capital and deducted in computing earnings per share. On September 1, 2022, the investor converted Series C Preferred into approximately 2 million shares of common stock, including accrued dividends.

 

9

 

Series D Convertible Preferred Stock

 

In June 2021, the Company received $1.5 million from an unrelated third party as an advance on a proposed sale of Series D Redeemable Convertible Preferred Stock. As of September 30, 2021, the Company was in the process of negotiating and finalizing the terms of the arrangement. As the agreement was not finalized as of September 30, 2021, the $1.5 million advance was classified as Advance from Investor within liabilities on the balance sheet at that time. As of December 31, 2021, the terms had been finalized, the investment was classified as equity, similar to the prior Convertible Preferred issuances, above. The issuance of the Series D Preferred generated a beneficial conversion feature (BCF), which arises when a debt or equity security is issued with an embedded conversion option that is beneficial to the investor or in the money at inception because the conversion option has an effective strike price that is less than the market price of the underlying stock at the commitment date. The fair value of the common stock into which the Series D Preferred was convertible exceeded the allocated purchase price fair value of the Series D Preferred Stock at the closing dates by approximately $0.3 million as of the closing dates. We recognized this BCF by allocating the intrinsic value of the conversion option, to additional paid-in capital, resulting in a discount on the Series D Preferred. As the Series D Preferred is immediately convertible, the Company accreted the discount on the date of issuance. The accretion was recognized as dividend equivalents. Holders of the Series D Preferred will be entitled to receive quarterly dividends at the annual rate of 8% of the stated value ($10 per share). Such dividends may be paid in cash or in shares of common stock at the Company’s discretion. In addition, 128,000 warrants to purchase the Company’s common stock were issued with respect to this transaction. These warrants are exercisable until December 1, 2024, at the lower of $1.75 per share or 85% of the variable price based on the ten day volume weighted average price (“VWAP”) of the Company’s common stock. The value of these warrants was determined to be $230,000 and recorded as an allocation of paid in capital associated with this transaction. On September 1, 2022, the investor converted Series D Preferred into approximately 1.8 million shares of common stock including accrued dividends.

 

Deposits and Note Conversion to Common Stock

 

In connection with the 2021 sale and leaseback transaction of the Company’s primary facility in Lake Barrington, IL, the landlord advanced rent payments in the form of a note. The balance of that note on December 31, 2022 was approximately $172,000. The note paid 3% interest and was due March 2024. In addition, the same entity made investment deposits during 2022 that were recorded as short term deposit liabilities. On February 1, 2023, our Board of Directors approved the conversion of these liabilities into common stock at a rate of approximately 84% of the volume weighted average price (VWAP) of the Company’s common stock during the period these deposits were received. In total, approximately $0.9 million of liabilities were converted into approximately 1.8 million shares of our common stock. Upon conversion, both the note and deposit liabilities were fully eliminated.

 

Warrants

 

In connection with the Series A Offering, in 2020 the Company issued 792,660 warrants to purchase 792,660 shares of the Company’s common stock for $1 per share. During 2020, warrants to acquire 597,500 shares of common stock were exercised in cash-less exchange for 391,308 shares of the Company’s common stock. In January and February 2021, the remaining warrants to acquire 195,160 shares of common stock were exercised in a cash-less exchange for 103,104 shares of the Company’s common stock. Additional warrants to acquire 128,000 shares of common stock were issued with respect to the Series D transaction above. These warrants can be exercised for the Company’s common stock for $1.75 per share, or based on the ten day volume weighted average price (VWAP) of the Company’s common stock.

 

The Company has applied the Black-Scholes model to value stock-based awards. That model incorporates various assumptions in the valuation of stock-based awards relating to the risk-free rate of interest to be applied, the estimated dividend yield and expected volatility of the Company’s Common Stock. The risk-free rate of interest is the U.S. Treasury yield curve for periods within the expected term of the option at the time of grant. The expected volatility is based on historical volatility of the Company’s Common Stock.

 

The valuation assumptions we have applied to determine the value of warrants granted in 2021 and 2020 were as follows:

 

  - Historical stock price volatility: The Company used the weekly closing price to calculate historical annual volatility which was a range from 68% - 167%.
     
  - Risk-free interest rate: The Company bases the risk-free interest rate on the rate payable on US treasury securities with a similar maturity in effect at the time of the grant, which was a range from .42% - 1.65%.
     
  - Expected life: The expected life of the warrants represents the period of time warrants were expected to be outstanding. The Company used an expected life of 5 years.
     
  - Dividend yield: The estimate for dividend yield is 0%, as the Company did not issue dividends during 2021 or 2020 and does not expect to do so in the foreseeable future.
     
  - Estimated forfeitures: When estimating forfeitures, the Company considers historical terminations as well as anticipated retirements.

 

10

 

A summary of the Company’s stock warrant activity is as follows:

Schedule of Company’s Stock Warrant Activity

   Shares under Option   Weighted Average Exercise Price 
Balance at December 31, 2022   128,000   $1.75 
Granted   -    - 
Cancelled/Expired   -    - 
Exercised/Issued   -    - 
Outstanding at March 31, 2023   128,000    1.75 
           
Exercisable at March 31, 2023   128,000   $1.75 

 

As of March 31, 2023 the Company reserved the following shares of its common stock for the exercise of warrants, and preferred stock:

Schedule of Reserved Shares of Exercise Warrants

2021 Warrants   128,000 
Shares reserved as of March 31, 2023   128,000 

 

Effective January 2022, and in accordance with the Employment Agreement of Chief Executive Officer Frank Cesario, a grant of restricted stock was made in the amount of 250,000 shares. 25,000 shares vested immediately, while the remaining 225,000 are subject to performance conditions as further detailed in the share grant. Specifically, the restrictions on the remaining 225,000 shares will lapse based on satisfaction of the following performance goals and objectives and continued employment through the date of meeting such targets:

 

● The restrictions on 56,250 shares of the award will lapse and the award will vest when the Company’s trailing-twelve-month EBITDA equals or exceeds $1 million at any time on or after January 1, 2022.

● The restrictions on 56,250 shares of the award will lapse and the award will vest in the event the Company’s common shares trade at or above $5/share for ten or more consecutive trading days.

● The restrictions on 56,250 shares of the award will lapse and the award will vest when the Company’s operating cash flow, calculated cumulatively from the date of employment, equals or exceeds $1.5 million. On January 30, 2023, the Compensation Committee determined this condition had been satisfied.

● The restrictions on 56,250 shares of the award will lapse and the award will vest in the event the Company is able to refinance its current lender with a traditional lender on terms and conditions customary for such financing. On August 23, 2022, the Compensation Committee determined this condition had been satisfied with an amended agreement with the Company’s lender.

 

During 2022 the Compensation Committee awarded the Chief Operating Officer a grant of 100,000 shares of restricted stock. 20,000 of these shares vested over a 12 month period while the remaining shares vest 20,000 each based on the performance conditions above.

 

The Audit Committee (as defined in the Plan) shall be responsible for determining when the conditions above have been satisfied. The Company records compensation expense with each vesting, and records a likelihood of vesting weighted analysis to the extent it has visibility to do so. Without such visibility, it considers such probability as de minimis until additional information is available.

 

Note 5 - Legal Proceedings

 

The Company may be party to certain lawsuits or claims arising in the normal course of business. The ultimate outcome of these matters is unknown but, in the opinion of management, we do not believe any of these proceedings will have, individually or in the aggregate, a material adverse effect upon our financial condition, cash flows or future results of operation.

 

11

 

Note 6 - Inventories

Schedule of Inventories

   March 31, 2023   December 31, 2022 
Raw materials  $1,374,000   $1,457,000 
Work in process   2,631,000    2,513,000 
Finished goods   3,939,000    4,355,000 
Total inventories  $7,944,000   $8,325,000 

 

Note 7 - Concentration of Credit Risk

 

Concentration of credit risk with respect to trade accounts receivable is generally limited due to the large number of entities comprising the Company’s customer base. The Company performs ongoing credit evaluations and provides an allowance for potential credit losses against the portion of accounts receivable which is estimated to be uncollectible. Such losses have historically been within management’s expectations. During the three months ended March 31, 2023 and 2022, there were two customers whose purchases represented more than 10% of the Company’s consolidated net sales. Sales to these customers for the three months ended March 31, 2023 and 2022 are as follows:

 

   Three Months Ended   Three Months Ended 
   March 31, 2023   March 31, 2022 
Customer  Net Sales  

% of Net

Sales

   Net Sales  

% of Net

Sales

 
Customer A  $2,563,000    50%  $2,502,000    43%
Customer B   1,652,000    32    1,347,000    23 

 

12

 

As of March 31, 2023, the total amounts owed to the Company by these customers was approximately $962,000 and $2,245,000, or 29% and 67% of the Company’s consolidated net accounts receivable, respectively. The amounts owed at March 31, 2022 by these customers were approximately $2,426,000 and $1,554,000, or 51% and 33%, respectively, of the Company’s consolidated net accounts receivable.

 

Note 8 - Related Party Transactions

 

John H. Schwan, who resigned as Chairman of the Board on June 1, 2020, has made loans to the Company which had outstanding balances of $1.3 million as of March 31, 2023 and December 31, 2022, respectively. No payments were made to Mr. Schwan since 2019. Interest expense related to this loan amounted to $18,000 and $16,000 for the three months end March 31, 2023 and 2022, respectively. Mr. Schwan is the father of Jana Schwan, the Company’s Chief Operating Officer.

 

Note 9 - Leases

 

We adopted ASC Topic 842 (Leases) on January 1, 2019. In July 2020, the Company entered into a lease agreement for a building through June 2021 (with no extension options). The monthly lease payments were $38,000. The Company made a policy election to not recognize right of use assets and lease liabilities that arise from leases with an initial term of twelve months or less on the Consolidated Balance Sheets. However, the Company recognized these lease payments in the Consolidated Statement of Operations on a straight-line basis over the lease term and variable lease payments in the period in which the expense was incurred. This lease terminated during 2021 and was replaced with a new lease. In March 2021, the Company entered into a lease agreement for a building through September 2022. This lease was subsequently extended during March 2022 to extend through December 31, 2025. The monthly lease payments are $35,000. The Company uses the incremental borrowing rate of 11%.

 

When this lease was extended during March 2022, the ROU (right of use) asset increased to $4,277,000, from $3,530,000 at December 31, 2021. The ROU liabilities also increased to $500,000 (current) and $3,777,000 (noncurrent), from $648,000 and $2,860,000, respectively, as of December 31, 2021.

 

Note 10 - Subsequent Events

 

The Company evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission.

 

During April 2023, the Company and Garden State Securities reached an agreement with respect to tail compensation associated with the Preferred Stock C investment and the 2019 agreement between the parties. The Company issued 125,000 shares of restricted stock to Garden State Securities. These are additional shares issued with no change in proceeds from that investment, and no impact on the investor or related conversion. With this transaction both parties have agreed to the conclusion of their agreement.

 

13

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward Looking Statements

 

This Quarterly Report on Form 10-Q includes both historical and “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future results. Words such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Quarterly Report on Form 10-Q. We disclaim any intent or obligation to update any forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform such statements to actual results or to changes in our opinions or expectations. These forward-looking statements are affected by factors, risks, uncertainties and assumptions that we make, including, without limitation, those discussed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 under the heading “Risk Factors.”

 

Overview

 

We produce film products for novelty, packaging and container applications. These products include foil balloons, latex balloons and related products, films for packaging and custom product applications, and flexible containers for packaging and consumer storage applications. We produce all of our film products for packaging, container applications and most of our foil balloons at our plant in Lake Barrington, Illinois. We used to produce our latex balloons and latex products at a majority-owned facility in Guadalajara, Mexico (Flexo Universal, or Flexo). This facility was sold during October 2021. Now the Company purchases latex balloons from an unrelated vendor and distributes in the United States, particularly to those customers that prefer a combined solution for foil and latex balloons.. Substantially all of our film products for packaging and custom product applications are sold to customers in the United States. We market and sell our novelty items, Candy Blossoms (balloons and candy arranged to look like a flower bouquet for gifting) and flexible containers for consumer use primarily in the United States.

 

Summary of Significant Events

 

September 30, 2021 financing

 

On September 30, 2021 (the “Closing Date”), the Company entered into a loan and security agreement (the “Agreement”) with Line Financial (the “Lender”), which provides for a senior secured financing consisting of a revolving credit facility (the “Revolving Credit Facility) in an aggregate principal amount of up to $6 million (the “Maximum Revolver Amount”) and term loan facility (the “Term Loan Facility”) in an aggregate principal amount of $731,250 (“Term Loan Amount” and, together with the Revolving Credit Facility, the “Senior Facilities”). Proceeds of loans borrowed under the Senior Facilities were used to repay all amounts outstanding under the Company’s prior Agreements and for the Company’s working capital. The Senior Facilities are secured by substantially all assets of the Company.

 

14

 

Interest on the Senior Facilities shall be the prime rate published from time to time published in the Wall Street Journal (8% as of March 31, 2023), plus 1.95% per annum, accruing daily and payable monthly. Interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. The Term Loan Facility shall be repaid by the Company to Lender in 48 equal monthly installments of principal and interest, each in the amount of $15,234, commencing on November 1, 2021, and continuing on the first day of each month thereafter until the Term Loan Maturity Date (as defined in the Agreement). Also, the Company will pay the Lender collateral monitoring fees of 4.62% of the eligible accounts receivable, inventory, and equipment supporting the Revolving Credit Facility and the Term Loan. In addition, the Company paid the Lender a loan fee of 1.25% of the Maximum Revolver Amount and the Term Loan Amount upon the execution of the Agreement. During August 2022 the terms were modified to reduce the collateral monitoring fee to 2.77% and added a provision that barred the Company from repaying the facility prior to September 2023.

 

The Senior Facilities mature on September 30, 2023 and shall automatically be extended for successive periods of one year each, unless the Company or the Lender gives the other party written notice of termination not less than 90 days prior to the end of such term or renewal term, as applicable. If the Senior Facilities are renewed, the Company shall pay the Lender a renewal fee of 1.25% of the Maximum Revolver Amount and the Term Loan Amount upon each renewal on the anniversary of the Closing Date. The Company has the option to prepay the Term Loan Facility (together with all accrued but unpaid interest and a Term Loan Prepayment Fee (as defined the Agreement) in whole, but not in part, upon not less than 60 days prior written notice to the Lender.

 

The Senior Facilities require that the Company shall, commencing December 31, 2021, maintain Tangible Net Worth of at least $4,000,000 or greater (“Minimum Tangible Net Worth”). Minimum Tangible Net Worth may be adjusted downward by the Lender, from time to time, in its sole and absolute discretion, based on the effect of non-cash charges and other factors on the calculation of Tangible Net Worth. Other debt subordinated to Lender is not considered as a reduction of this calculation. The Company believes it was in compliance with this covenant during every relevant month, including as of December 31, 2022 and March 31, 2023.

 

The Senior Facilities contain certain affirmative and negative covenants that limit the ability of the Company, among other things and subject to certain significant exceptions, to incur debt or liens, make investments, enter into certain mergers, consolidations, and acquisitions, pay dividends and make other restricted payments, or make capital expenditures exceeding $1 million in the aggregate in any fiscal year.

 

As of March 31, 2023 and December 31, 2022, the term loan balance amounted to $0.5 million, which consisted of the principal and interest payable balance of $0.6 million and deferred financing costs of $0.1 million. The balance of the Revolving Line of Credit as of March 31, 2023 and December 31, 2022 amounted to $4.3 and $2.9 million, respectively.

 

15

 

Results of Operations

 

Net Sales. For the three month periods ended March 31, 2023 and 2022, net sales were $5,051,000 and $5,797,000, respectively.

 

For the three-month period ended March 31, 2023 and 2022, net sales by product category were as follows:

 

   Three Months Ended         
   March 31, 2023   March 31, 2022         
   $   % of   $   % of         
   (000)   Net   (000)   Net       % 
Product Category  Omitted   Sales   Omitted   Sales   Variance   change 
                         
Foil Balloons  $3,474    69%  $3,832    66%  $(358)   (9)%
                               
Film Products   89    2%   828    14%   (739)   (89)%
                               
Other  $1,488    29%  $1,112    19%  $376    34%
                               
Total  $5,051    100%  $5,797    100%  $(746)   (13)%

 

Foil Balloons. Revenues from the sale of foil balloons decreased during the three-month period from $3,832,000 ending March 31, 2022 compared to $3,474,000 during the three month period of 2023. While the price of helium has reduced from its 2022 peak, it remains elevated from the beginning of 2022, which negatively impacts the demand for balloons primarily filled with helium.

 

Films. Revenues from the sale of commercial films decreased, from $828,000 during the three-month period ended March 31, 2022, compared to $89,000 during the same period of 2023. The Company’s largest customer increased its demand for the line that the Company supplies in 2022 and finished the year with inventory, negatively impacting early 2023 orders.

 

Other Revenues. Revenues from the sale of other products were $1,112,000 during the three-month period ended March 31, 2022, compared to $1,488,000 during the same period of 2023. The revenues from the sale of other products during these periods include (i) sales of a line of “Candy Blossoms” and similar products consisting of candy and small inflated balloons sold in small containers and (ii) the sale of accessories and supply items related to balloon products.

 

Sales to a limited number of customers continue to represent a large percentage of our net sales. The table below illustrates the impact on sales of our top three and ten customers for the three month periods ended March 31, 2023 and 2022.

 

   Three Months Ended March 31, 
   % of Sales 
   2023   2022 
         
Top 3 Customers   86%   80%
           
Top 10 Customers   91%   90%

 

16

 

During the three-month period ended March 31, 2023, there were two customers whose purchases represented more than 10% of the Company’s consolidated net sales. Sales to these customers for the three month period ended March 31, 2023 were $2,563,000 and $1,652,000, or 50% and 32%, respectively, of consolidated net sales. Sales to these customers for the three months ended March 31, 2022 were $2,502,000 and $1,347,000, or 43% and 23%, respectively of consolidated net sales. As of March 31, 2023, the total amount owed to the Company by these customers was approximately $962,000 and $2,245,000, or 29% and 67%, respectively of the Company’s consolidated net accounts receivable. The amount owed at March 31, 2022 by these customers was approximately $696,000 and $1,669,000, or 20% and 48%, respectively, of the Company’s consolidated net accounts receivable.

 

Cost of Sales. During the three month period ended March 31, 2023, the cost of sales was $3,924,000, compared to $4,758,000 for the same period of 2022 due to lower sales volume and increased cost and mix efficiencies during 2023.

 

General and Administrative. During the three month period ended March 31, 2023, general and administrative expenses were $961,000 as compared to $837,000 for the same period in 2022. The Company incurred start up expenses with a new audit firm partner during 2023 as well as transition cost inefficiencies.

 

Selling, Advertising and Marketing. During the three month period ended March 31, 2023, selling, advertising and marketing expenses were $154,000 as compared to $221,000 for the same period in 2022. The Company made small investments during 2022 that were not repeated during 2023.

 

Other Income (Expense). During the three month period ended March 31, 2023, the Company incurred interest expense of $142,000 as compared to interest expense of $96,000 during the same period of 2022. The dramatic increase in interest rates during 2022 flowed through to the Company’s Prime interest rate based borrowing structure.

 

Financial Condition, Liquidity and Capital Resources

 

Cash Flow Items.

 

Operating Activities. During the three months ended March 31, 2023, net cash used by operations was $1,369,000, compared to net cash provided by operations during the three months ended March 31, 2022 of $2,000.

 

Significant changes in working capital items during the three months ended March 31, 2023 included:

 

  ● An increase in accounts receivable of $1,726,000 compared to a decrease in accounts receivable of $125,000 in the same period of 2022.
     
  ● An decrease in inventory of $381,000 compared to an increase in inventory of $620,000 in 2022.
     
  ● An increase in trade payables of $35,000 compared to an increase in trade payables of $215,000 in 2022.
     
  ● An increase in prepaid expenses and other assets of $100,000 compared to a decrease of $339,000 in 2022.
     
  ● A decrease in accrued liabilities of $372,000 compared to a decrease in accrued liabilities of $165,000 in 2022.

 

Investing Activity. During the three months ended March 31, 2023, cash used in investing activity was $56,000, compared to cash used in investing activity for the same period of 2022 in the amount of $15,000.

 

Financing Activities. During the three months ended March 31, 2023, cash provided by financing activities was $1,409,000 compared to cash provided by financing activities for the same period of 2022 in the amount of $155,000. Financing activity during 2023 consisted principally of changes in the balances of revolving and long-term debt.

 

Liquidity and Capital Resources.

 

At March 31, 2023, the Company had cash balances of $130,000 compared to cash balances of $208,000 for the same period of 2022.

 

17

 

The ability of the Company to continue as a going concern is dependent on the Company executing its business plan and, if unable to do so, in obtaining adequate capital on acceptable terms to fund any operating losses. Management’s plans to continue as a going concern include executing its business plan, continuing to focus our Company on the most profitable elements, and exploring alternative funding sources on an as needed basis. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The COVID-19 pandemic, supply chain constraints, inflationary pressures, and the cost and commercial availability of helium have impacted the Company’s business operations to some extent and is expected to continue to do so and, these impacts may include reduced access to capital. The ability of the Company to continue as a going concern is dependent upon its ability to successfully generate or otherwise secure other sources of financing and attain profitable operations. There is substantial doubt about the ability of the Company to continue as a going concern for one year from the issuance of the accompanying consolidated financial statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The Company’s primary sources of liquidity have traditionally been comprised of cash and cash equivalents as well as availability under the Credit Agreement. We believe that we have been in compliance with covenants since refinancing with Line Financial in September 2021. That Credit Agreement expires per its terms on September 30, 2023, unless it is extended by the parties or replaced. While the Company expects to find an acceptable credit facility, there can be no assurance of success, and as such, might negatively impact the Company’s ability to continue as a going concern.

 

Seasonality

 

In the foil balloon product line, sales have historically been seasonal with approximately 40% occurring in the period from December through March of the succeeding year and 24% being generated in the period July through October in recent years.

 

Please see pages 11-20 of our Annual Report on Form 10-K for the year ended December 31, 2022 for a description of policies that are critical to our business operations and the understanding of our results of operations. The impact and any associated risks related to these policies on our business operations is discussed throughout Management’s Discussion and Analysis of Financial Condition and Results of Operations where such policies affect our reported and expected financial results. No material changes to such information have occurred during the three months ended March 31, 2023.

 

Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

(a) Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules and forms.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer) and Acting Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of March 31, 2021. Based on this evaluation, the Chief Executive Officer (principal executive officer) and Acting Chief Financial Officer (principal financial officer) concluded that our disclosure controls and procedures were not effective as of March 31, 2023, the end of the period covered by this Quarterly Report on Form 10-Q due to the material weaknesses described below.

 

18

 

(b) Management’s Report on Internal Control over Financial Reporting

 

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.

 

Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Management has assessed the effectiveness of our internal control over financial reporting as of March 31, 2023. In making our assessment of the effectiveness of internal control over financial reporting, management used the criteria set forth in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

 

A material weakness is a control deficiency, or combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the registrant’s annual or interim financial statements will not be prevented or detected on a timely basis. As a result of our evaluation of our internal control over financial reporting, management identified the following material weaknesses in our internal control over financial reporting:

 

  ● We lacked a sufficient number of accounting professionals with the necessary knowledge, experience and training to adequately account for significant, unusual transactions that resulted in misapplications of GAAP, particularly with regard to the timing of recognition of certain non-cash charges, and
     
  ● We are overly dependent upon our Acting Chief Financial Officer, who at present is our Chief Executive Officer, within an environment that is highly manual in nature.

 

As a result of the material weaknesses, we have concluded that we did not maintain effective internal control over financial reporting as of March 31, 2023.

 

Part II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company may be party to certain lawsuits or claims arising in the normal course of business. The ultimate outcome of these matters is unknown but, in the opinion of management, we do not believe any of these proceedings will have, individually or in the aggregate, a material adverse effect upon our financial condition, cash flows or future results of operation.

 

Item 1A. Risk Factors

 

Not applicable.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Not applicable.

 

Item 3. Defaults Upon Senior Securities

 

The Company believes that it has been in compliance with the terms of the Line Capital financing since inception on September 30, 2021.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

19

 

Item 6. Exhibits

 

The following are being filed as exhibits to this report:

 

Exhibit

Number

   Description
     
31.1*   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and rule 15d-14(a) of the Securities Exchange Act, as amended (filed herewith).
31.2*   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and rule 15d-14(a) of the Securities Exchange Act, as amended (filed herewith).
32**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
101*   Interactive Data Files, including the following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in inline XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Cash Flows, and (iv) the Notes to Consolidated Financial Statements.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
     
*   Filed herewith
**   furnished herewith

 

20

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 15, 2023 Yunhong CTI Ltd.
   
 

By:

 /s/ Frank J. Cesario
    Frank J. Cesario
    Chief Executive Officer
     
  By: /s/ Frank J. Cesario
    Frank J. Cesario
    Acting Chief Financial Officer

 

21

 

Yunhong CTI (NASDAQ:CTIB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Yunhong CTI Charts.
Yunhong CTI (NASDAQ:CTIB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Yunhong CTI Charts.